European Commission approves Merck's Keytruda plus Padcev for muscle-invasive bladder cancer

Merck received European Commission approval for KEYTRUDA in combination with Padcev for adults with resectable muscle-invasive bladder cancer.

Detected & updated continuously · Source: Nebula